+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015

  • ID: 3165004
  • Report
  • March 2015
  • 42 pages
  • Global Markets Direct
1 of 5
Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015

Summary

This, ‘Chemotherapy Induced Myelosuppression - Pipeline Review, H1 2015’, provides an overview of the Chemotherapy Induced Myelosuppression’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Myelosuppression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Myelosuppression and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Myelosuppression
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Chemotherapy Induced Myelosuppression and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Chemotherapy Induced Myelosuppression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chemotherapy Induced Myelosuppression pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Myelosuppression
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Myelosuppression pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5
List of Tables
List of Figures
Introduction
REPORT COVERAGE
Chemotherapy Induced Myelosuppression Overview
Therapeutics Development
Pipeline Products for Chemotherapy Induced Myelosuppression - Overview
Pipeline Products for Chemotherapy Induced Myelosuppression - Comparative Analysis
Chemotherapy Induced Myelosuppression - Therapeutics under Development by Companies
Chemotherapy Induced Myelosuppression - Therapeutics under Investigation by Universities/Institutes
Chemotherapy Induced Myelosuppression - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Chemotherapy Induced Myelosuppression - Products under Development by Companies
Chemotherapy Induced Myelosuppression - Products under Investigation by Universities/Institutes
Chemotherapy Induced Myelosuppression - Companies Involved in Therapeutics Development
Biothera, Inc.
G1 Therapeutics, Inc.
Chemotherapy Induced Myelosuppression - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
calcitriol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
G-1T28 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GZ-381 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imprime PGG - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Chemotherapy Induced Myelosuppression - Recent Pipeline Updates
Chemotherapy Induced Myelosuppression - Dormant Projects
Chemotherapy Induced Myelosuppression - Product Development Milestones
Featured News & Press Releases
Apr 07, 2014: Research Expands Understanding of Biomarker for Biothera Cancer Immunotherapy Imprime PGG
Jun 12, 2012: Biothera Discovers Biomarker For The Cancer Drug Imprime PGG
Jun 06, 2012: Imprime PGG Binds To Adaptive Immune Cells
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Chemotherapy Induced Myelosuppression, H1 2015
Number of Products under Development for Chemotherapy Induced Myelosuppression - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Chemotherapy Induced Myelosuppression - Pipeline by Biothera, Inc., H1 2015
Chemotherapy Induced Myelosuppression - Pipeline by G1 Therapeutics, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Chemotherapy Induced Myelosuppression Therapeutics - Recent Pipeline Updates, H1 2015
Chemotherapy Induced Myelosuppression - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Chemotherapy Induced Myelosuppression, H1 2015
Number of Products under Development for Chemotherapy Induced Myelosuppression - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015
Note: Product cover images may vary from those shown
4 of 5
Biothera, Inc.
G1 Therapeutics, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll